Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013
Antares Pharma, Inc. today reported operating and financial results for the fourth quarter and full year ended December 31, 2013.
Antares Pharma Receives Second Milestone Payment from LEO Pharma in OTREXUP Collaboration
The milestone payment was received in connection with the launch of OTREXUP and the achievement of a specific percentage of patient lives covered by managed care organizations.
Otrexup (Methotrexate Injection) Launched for Treatment of Psoriasis in Adults
Otrexup is now available to dermatologists for use in adults who need symptomatic control of severe recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy.
SMC Issues a Positive Recommendation for Stelaraa (Ustekinumab) in...
FOR MEDICAL TRADE MEDIA ONLY Janssen UK announced today that the Scottish Medicines Consortium has recommended the use of Stelara A for the treatment of active psoriatic arthritis in adult patients in NHS Scotland.
Customer Interaction Solutions
Antares Pharma Announces LEO Pharma's Launch of OTREXUP...
Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous methotrexate product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Methotrexate with infliximab in patients with Crohn's disease
Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease, reports the most recent issue of Gastroenterology.